Surfing the MASH Tsunami
Driving the Discussion in Fatty Liver Disease. Join hepatology researcher and Key Opinion Leader Jörn Schattenberg, Liver Wellness Advocate Louise Campbell, and Forecasting and Pricing Guru Roger Green and a global group of Key Opinion Leaders and patient advocates as they discuss key issues in Fatty Liver disease, including epidemiology, drug development, clinical pathways, non-invasive testing, health economics and regulatory issues, from their own unique perspectives on the Surfing the MASH Tsunami podcast. #MASH #MAFLD #FattyLiver #livertwitter #AASLD #GlobalLiver #NoNASH #EASL
Episodes
1040 episodes
S6 - E5.2 - Newsmaker: Naga Chalasani on Real-World Experience Prescribing Resmetirom
This weekend’s Newsmaker, Indiana University hepatologist and key opinion leader Naga Chalasani, joins Roger Green to discuss Early Experience with Resmetirom To Treat Metabolic-Associated Steatohepatitis with Fibrosis in a Real-World Setting, ...
•
Season 6
•
Episode 5
•
26:18
S6 - E5.3 - Expert: Scott Friedman on Gene Therapy and Advances in Liver Science
This week’s expert, Hepatologist and Key Opinion Leader Scott Friedman, joins Roger to discuss advances in acceptance of gene therapy and knowledge in other areas of basic liver science. When discussing science, he pays particular attention to ...
•
Season 6
•
Episode 5
•
23:23
S6 - E5.1 - FGF-21s and A Promising Future on Cirrhosis
This conversation is the opening segment of SurfingMASH's April discussion, in memory of Stephen A. Harrison, on drug development. In addition to co-hosts Jörn Schattenberg, Louise Campbell and Roger Green, panelists include hepatologists and k...
•
Season 6
•
Episode 5
•
24:24
S6 - E5 - Drug Development Week: FGF-21s, Cirrhosis, Resmiterom, Gene Therapies
00:00:00 - Surf's Up: Season 6 Episode 5Host Roger Green briefly describes this episode’s three sections and introduces Roundtable guests. The Roundtable panel shares groundbreakers. 00:10:39 - Roundtable: A Deep Dive Into Dr...
•
Season 6
•
Episode 5
•
1:09:00
S6 - E4.3 - Expert: Mazen Noureddin Reviews the Exciting MASLD Drug Development Environment
This week's expert, Hepatologist and Key Opinion Leader Mazen Noureddin, joins Roger to discuss major advances in drug development over the past year. He covers a range of different drug classes, focusing on stages of development and the range ...
•
Season 6
•
Episode 4
•
24:34
S6 - E4.2 - Newsmaker: Fatty Liver Alliance Founder Mike Betel Discusses the Increased Visibility of Patient Advocates
This weekend's Newsmaker, Fatty Liver Alliance Founder Mike Betel, joins Roger Green to discuss the wide range of conferences where he has been invited to speak or sit on a panel this year. Specifically, he shares his belief on what this says a...
•
Season 6
•
Episode 4
•
31:16
S6 - E4.1 - MASLD Drugs, SLD Spectrum Insights Suggest Bright Future
This conversation is the concluding segment of SurfingMASH's coverage of the AASLD Emerging Trends Conference on the SLD Spectrum diseases: MASLD, MetALD and ALD. In addition to co-hosts Louise Campbell and Roger Green, panelists include ...
•
Season 6
•
Episode 4
•
20:58
S6 - E4 - Reasons for optimism in MASLD drug development and patient advocacy
00:00:00 - Surf's Up: Season 6 Episode 4 Surfing the MASH Tsunami concludes its coverage of the AASLD Emerging Trends Conference on MASLD, MetALD and ALD. This week, the panelists focus on pivotal messages that attendees took away f...
•
Season 6
•
Episode 4
•
1:12:42
S6 - E3.3 - Expert: GLI's Jeff McIntyre discusses implications of FDA job cuts on MASH drugs
This week's Expert is Jeff McIntyre, Vice President, Liver Programs at the Global Liver Institute. His major topic is how recent high-level FDA job cuts might affect MASH drug and diagnostics development. He also shares reactions to FibroSIGHT,...
•
Season 6
•
Episode 3
•
31:31
S6 E3.2 - Newsmakers: FibroSIGHT™ Brings Clinical Trial Analytics to the Clinic
This week's newsmaker, Yukti Choudhury, Director of Clinical Development at HistoIndex, joins Roger Green to discuss FibroSIGHT, a new HistoIndex service that allows clinicians to use HistoIndex's Second Harmonic Generation (SHG) technology and...
•
Season 6
•
Episode 3
•
28:57
S6- E3.1 - Roundtable: Spotting Tomorrow’s Trends in Today's MASLD Studies
Surfing the MASH Tsunami continues its coverage of the AASLD Emerging Trends Conference on MASLD, MetALD and ALD. This week, the panelists focus on what studies on bariatric surgery and drugs in development can tell us about future ...
•
Season 6
•
Episode 3
•
15:02
S6 - E3 - Drugs and Diagnostics Evolve as the FDA Devolves
00:00:00 - Surf's Up: Season 6 Episode 3Surfing the MASH Tsunami continues its coverage of the AASLD Emerging Trends Conference on MASLD, MetALD and ALD. This week, the panelists focus on what studies on bariatric surgery and drugs in de...
•
Season 6
•
Episode 3
•
1:12:31
S6 - E2 - MetALD Epidemiology, MASLD Mortality and a PCP "Unicorn"
00:00:00 - Surf's Up: Season 6 Episode 2Surfing the MASH Tsunami continues its coverage of the AASLD Emerging Trends Conference on MASLD, MetALD and ALD. This week, the panelists focus on disease epidemiology and what it can teach us abo...
•
Season 6
•
Episode 2
•
1:11:36
S6 - E1: Two Multispecialty February Conferences and Europe Prepares for Resmetirom
00:00:00 - Surf's Up! Season 6 Episode 1SurfingMASH kicks off our sixth season in our new format, with three major elements to each episode. This week's Roundtable and Newsmakers segments focused on two recent conferences that took a mul...
•
Season 6
•
Episode 1
•
1:13:24
S5 - E26.5 - Looking Back at #TLM2024 - Promoting Healthy Livers and Looking Ahead to 2025
In this episode, Naim Alkhouri, Mike Betel, Michelle Long and Jeff McIntyre join Jörn Schattenberg and Roger Green to look back at The Liver Meeting 2024. This conversation reviews two sessions promoting healthy livers and asks panelists what t...
•
Season 5
•
Episode 26
•
15:18
S5 - E26.4 - Looking Back at #TLM2024 - Patient Advocacy and Patient-Centric Trials
In this episode, Naim Alkhouri, Mike Betel, Michelle Long and Jeff McIntyre join Jörn Schattenberg and Roger Green to look back at The Liver Meeting 2024. This conversation considers the role of patient advocacy in replacing biopsy in clinical ...
•
Season 4
•
Episode 26
•
11:44
S5 - E26.3 - Looking Back at #TLM2024 - FGF-21 Agents and the FDA Corner
In this episode, Naim Alkhouri, Mike Betel, Michelle Long and Jeff McIntyre join Jörn Schattenberg and Roger Green to look back at The Liver Meeting 2024. This conversation reviews the late-breaker presentation on efimosermin, a q4w FGF-21 agen...
•
Season 5
•
Episode 26
•
13:18
S5 - E26.2 - Looking Back at #TLM2024 - Patient Genotyping and MASH Clusters
In this episode, Naim Alkhouri, Mike Betel, Michelle Long and Jeff McIntyre join Jörn Schattenberg and Roger Green to look back at The Liver Meeting 2024. This conversation considers how the anticipated approval of a second MASH drug without bi...
•
Season 5
•
Episode 26
•
14:27
S5 - E26.1 - Looking Back at #TLM2024 - Semaglutide Passes the ESSENCE Test
In this episode, Naim Alkhouri, Mike Betel, Michelle Long and Jeff McIntyre join Jörn Schattenberg and Roger Green to look back at The Liver Meeting 2024. This conversation reviews the ESSENCE trial, the Phase 3 trial demonstrating that semaglu...
•
Season 5
•
Episode 26
•
13:32
S5-26 - One Month Later: Looking Back at MASLD/MASH Coverage From The Liver Meeting 2024
00:00:00 – Surf’s Up: Season 5 Episode 26 - Last month, close to 8,000 hepatology stakeholders convened in San Diego for The Liver Meeting 2024. Hepatology Key Opinion Leader Naim Alkhouri, Novo Nordisk International Vice President for Medicine...
•
Season 5
•
Episode 26
•
1:11:25
S5 - E25 - Reviewing Expert Recommendations on the Use of Resmetirom
00:00:00 - Surf's Up: Season 5 Episode 25 On July 20, Clinical Gastroenterology and Hepatology released the paper, Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patien...
•
Season 5
•
Episode 25
•
42:02
S4 - E24.5 - SurfingMASH Question of The Week: Keys to Improving Provider-Patient Communication
Two weeks ago, the SurfingMASH Question of the Week asked, "What structural or educational changes do you anticipate will significantly improve Provider-Patient communication? Will these changes require more from the provider and more from the ...
•
Season 5
•
Episode 24
•
20:14
S5 - E24.4 - EASL Congress Six Weeks Later: Jeff McIntyre's Key Implications for GLI
In the second half of Roger Green's interview with Global Liver Institute Vice President, Liver Programs Jeff McIntyre, Jeff discusses the implications of his key EASL Congress takeaways for GLI and other patient advocacy groups. ...
•
Season 5
•
Episode 24
•
18:28
S5 - E24.3 - EASL Congress Six Weeks Later: Jeff McIntyre's Key Takeaways
This conversation contains the first half of Roger Green's interview with Global Liver Institute Vice President, Liver Programs Jeff McIntyre, during which the two discuss what Jeff considered the key strategic takeaways for GLI from the variou...
•
Season 5
•
Episode 24
•
12:46
S5 - E24.2 - EASL Congress Six Weeks Later: Mathieu Petitjean's Key Implications
In the second half of Roger Green's interview with PharmaNest Founder and CEO Mathieu Petitjean, Matt discusses the implications of his key EASL Congress takeaways for PharmaNest. Matt starts this discussion with a simple question...
•
Season 5
•
Episode 24
•
10:58